FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression

NCT07540988 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

466

Enrollment

INDUSTRY

Sponsor class

Conditions

Interstitial Lung Diseases

Interventions

DRUG: Nerandomilast
DRUG: Placebo matching nerandomilast

Sponsor

Boehringer Ingelheim